跳至主要内容
临床试验/EUCTR2021-003776-13-LT
EUCTR2021-003776-13-LT进行中(未招募)1 期

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication - KARDIA-2

Alnylam Pharmaceuticals, Inc.0 个研究点目标入组 1,800 人开始时间: 2021年11月29日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age 18 to 75 years, inclusive, at time of initial informed consent
  • -24-hour mean SBP=130 mmHg and =160 mmHg by ABPM at Run-in Visit 2 after at least 4 weeks of run-in
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1500
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 300

排除标准

  • -Secondary hypertension, orthostatic hypotension
  • -Elevated potassium >5 mEq/L
  • -eGFR of =30 mL/min/1.73m2
  • -Received an investigational agent within the last 30 days
  • -Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus
  • -History of any cardiovascular event within 6 months prior to randomization
  • -History of intolerance to subcutaneous injection(s)

研究者

相似试验

A Study to Evaluate Efficacy and Safety of... | 临床试验